NVRO - Nevro Corp.

NYSE - NYSE Delayed price. Currency in USD
84.54
+0.84 (+1.00%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous close83.70
Open83.32
Bid0.00 x 1100
Ask0.00 x 800
Day's range82.19 - 84.70
52-week range65.00 - 94.34
Volume313,563
Avg. volume459,989
Market cap2.534B
Beta-0.07
PE ratio (TTM)N/A
EPS (TTM)-1.35
Earnings date6 Aug 2018 - 10 Aug 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est93.70
Trade prices are not sourced from all markets
  • Shocking the Spine Offers an Alternative to Opioids
    Bloomberglast month

    Shocking the Spine Offers an Alternative to Opioids

    Like millions of people caught up in America’s opioid crisis, Rick Surkin used to take a pill just to get out of bed in the morning. Until last year, the former firefighter relied on thrice-daily doses of the powerful painkiller OxyContin to numb the agony from a ruptured disc in his back. The series of tiny shocks, known as neuromodulation, has kept Surkin comfortable enough to ditch Oxy.

  • Why Nevro Corp. Is Sinking Today
    Motley Foollast month

    Why Nevro Corp. Is Sinking Today

    Shares tumble after the company reports first-quarter results. Here's what investors need to know.

  • Associated Presslast month

    Nevro: 1Q Earnings Snapshot

    REDWOOD CITY, Calif. (AP) _ Nevro Corp. (NVRO) on Monday reported a loss of $17.7 million in its first quarter. On a per-share basis, the Redwood City, California-based company said it had a loss of 59 cents. The results missed Wall Street expectations.

  • These medical devices are getting better at treating chronic pain
    CNBC3 months ago

    These medical devices are getting better at treating chronic pain

    Spinal cord stimulation isn't as scary as it sounds. Innovation in the devices and a push away from treating chronic pain with opioids are causing the market to boom.

  • Should You Buy Nevro (NVRO) Ahead of Earnings?
    Zacks4 months ago

    Should You Buy Nevro (NVRO) Ahead of Earnings?

    Nevro (NVRO) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

  • What’s ahead for Abbott Laboratories’ Medical Device Unit?
    Market Realist4 months ago

    What’s ahead for Abbott Laboratories’ Medical Device Unit?

    What's Next for Abbott Laboratories after a Stellar 2017?

  • Associated Press7 months ago

    Nevro reports 3Q loss

    The Redwood City, California-based company said it had a loss of 21 cents per share. The results surpassed Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment ...

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes